Retinoid X Receptor Gamma Control of Affective Behaviors Involves Dopaminergic Signaling in Mice

Neuron

Volumn 66, Issue 6, 2010, Pages 908-920

  Krzyzosiak, Agnieszka ^a,b,c   Szyszka Niagolov, Monika ^a,b   Wietrzych, Marta ^a,b   Gobaille, Serge ^b   Muramatsu, Shin ichi ^d   Krezel, Wojciech ^a,b  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^d JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Humdisease; Molneuro

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; HALOPERIDOL; PARVOVIRUS VECTOR; PROTEIN C FOS; RACLOPRIDE; RETINOID X RECEPTOR GAMMA; SEROTONIN;

ACTIMETRY; AFFECT; ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CATALEPSY; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOPELESSNESS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CELL COUNT; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; FOOD PREFERENCES; GENE EXPRESSION REGULATION; HALOPERIDOL; IMMOBILITY RESPONSE, TONIC; MICE; MICE, KNOCKOUT; MOOD DISORDERS; NUCLEUS ACCUMBENS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, DOPAMINE D2; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTOR GAMMA; RNA, MESSENGER; SEROTONIN; SIGNAL TRANSDUCTION;

EID: 77953951450     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2010.05.004     Document Type: Article

References (49)

1. Ainsworth K., Smith S.E., Zetterström T.S., Pei Q., Franklin M., Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl.) 1998, 140:470-477.
2. Amalric M., Koob G.F. Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system. Prog. Brain Res. 1993, 99:209-226.
3. Blier P., Ward N.M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol. Psychiatry 2003, 53:193-203.
4. Blier P., Piñeyro G., el Mansari M., Bergeron R., de Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann. N Y Acad. Sci. 1998, 861:204-216.
5. Bremner J.D., McCaffery P. The neurobiology of retinoic acid in affective disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:315-331.
6. Brocco M., Dekeyne A., Papp M., Millan M.J. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav. Pharmacol. 2006, 17:559-572.
7. Carlezon W.A., Mague S.D., Parow A.M., Stoll A.L., Cohen B.M., Renshaw P.F. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol. Psychiatry 2005, 57:343-350.
8. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 2000, 11:58-65.
9. Dailly E., Chenu F., Renard C.E., Bourin M. Dopamine, depression and antidepressants. Fundam. Clin. Pharmacol. 2004, 18:601-607.
10. Dalvi A., Lucki I. Murine models of depression. Psychopharmacology (Berl.) 1999, 147:14-16.
11. de Urquiza A.M., Liu S., Sjöberg M., Zetterström R.H., Griffiths W., Sjövall J., Perlmann T. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000, 290:2140-2144.
12. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
13. Dziedzicka-Wasylewska M., Rogoz R., Klimek V., Maj J. Repeated administration of antidepressant drugs affects the levels of mRNA coding for D1 and D2 dopamine receptors in the rat brain. J. Neural Transm. 1997, 104:515-524.
14. Foley K.F., DeSanty K.P., Kast R.E. Bupropion: pharmacology and therapeutic applications. Expert Rev. Neurother. 2006, 6:1249-1265.
15. Kastner P., Mark M., Ghyselinck N., Krezel W., Dupé V., Grondona J.M., Chambon P. Genetic evidence that the retinoid signal is transduced by heterodimeric Rxr/Rar functional units during mouse development. Development 1997, 124:313-326.
16. Kontaxakis V.P., Skourides D., Ferentinos P., Havaki-Kontaxaki B.J., Papadimitriou G.N. Isotretinoin and psychopathology: a review. Ann. Gen. Psychiatry 2009, 8:2.
17. Krezel W., Dupé V., Mark M., Dierich A., Kastner P., Chambon P. Rxr gamma null mice are apparently normal and compound Rxr alpha +/-/Rxr beta -/-/Rxr gamma -/- mutant mice are viable. Proc. Natl. Acad. Sci. USA 1996, 93:9010-9014.
18. Krezel W., Ghyselinck N., Samad T.A., Dupé V., Kastner P., Borrelli E., Chambon P. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 1998, 279:863-867.
19. Krezel W., Kastner P., Chambon P. Differential expression of retinoid receptors in the adult mouse central nervous system. Neuroscience 1999, 89:1291-1300.
20. Larisch R., Klimke A., Vosberg H., Löffler S., Gaebel W., Müller-Gärtner H.W. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage 1997, 5:251-260.
21. Lechin F., van der Dijs B., Hernandez-Adrian G. Dorsal raphe vs. median raphe serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological, neuropharmacological and clinical evidences: relevance for neuropharmacological therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:565-585.
22. Lengqvist J., Mata De Urquiza A., Bergman A.C., Willson T.M., Sjövall J., Perlmann T., Griffiths W.J. Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain. Mol. Cell. Proteomics 2004, 3:692-703.
23. Li X.G., Okada T., Kodera M., Nara Y., Takino N., Muramatsu C., Ikeguchi K., Urano F., Ichinose H., Metzger D., et al. Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Mol. Ther. 2006, 13:160-166.
24. Logan A.C. Omega-3 fatty acids and major depression: a primer for the mental health professional. Lipids Health Dis. 2004, 3:25.
25. Lucki I., Dalvi A., Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001, 155:315-322.
26. Mattes J.A. Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. Ann. Clin. Psychiatry 1997, 9:87-88.
27. Messier C., Mrabet O., Destrade C. Locomotor bias produced by intra-accumbens injection of dopamine agonists and antagonists. Pharmacol. Biochem. Behav. 1992, 41:177-182.
28. Millan M.J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 2006, 110:135-370.
29. Millan M.J., Seguin L., Gobert A., Cussac D., Brocco M. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl.) 2004, 174:341-357.
30. Moreau J.L. Reliable monitoring of hedonic deficits in the chronic mild stress model of depression. Psychopharmacology (Berl.) 1997, 134:357-358.
31. Naliwaiko K., Araújo R.L., da Fonseca R.V., Castilho J.C., Andreatini R., Bellissimo M.I., Oliveira B.H., Martins E.F., Curi R., Fernandes L.C., Ferraz A.C. Effects of fish oil on the central nervous system: a new potential antidepressant?. Nutr. Neurosci. 2004, 7:91-99.
32. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59:1151-1159.
33. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., Hen R., Koester S., Lederhendler I., Meaney M., et al. Preclinical models: status of basic research in depression. Biol. Psychiatry 2002, 52:503-528.
34. Ouagazzal A.M., Creese I. Intra-accumbens infusion of D(3) receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacol. Biochem. Behav. 2000, 67:637-645.
35. Paterna J.C., Feldon J., Büeler H. Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J. Virol. 2004, 78:6808-6817.
36. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego, CA.
37. Peet M., Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005, 65:1051-1059.
38. Pijnenburg A.J., Honig W.M., Van der Heyden J.A., Van Rossum J.M. Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur. J. Pharmacol. 1976, 35:45-58.
39. Rasband, W.S. (1997). ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 1997-2009. http://rsb.info.nih.gov/ij/.
40. Renard C.E., Fiocco A.J., Clenet F., Hascoet M., Bourin M. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?. Psychopharmacology (Berl.) 2001, 159:42-50.
41. Samad T.A., Krezel W., Chambon P., Borrelli E. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc. Natl. Acad. Sci. USA 1997, 94:14349-14354.
42. Siuciak J.A., Fujiwara R.A. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology (Berl.) 2004, 175:163-169.
43. Theohar C., Fischer-Cornelssen K., Brosch H., Fischer E.K., Petrovic D. A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression. Arzneimittelforschung 1982, 32:783-787.
44. Valentini V., Frau R., Di Chiara G. Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J. Neurochem. 2004, 88:917-927.
45. Wietrzych M., Meziane H., Sutter A., Ghyselinck N., Chapman P.F., Chambon P., Krezel W. Working memory deficits in retinoid X receptor gamma-deficient mice. Learn. Mem. 2005, 12:318-326.
46. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol. 1997, 12(Suppl 3):S7-S14.
47. Willner P., Hale A.S., Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J. Affect. Disord. 2005, 86:37-45.
48. Zetterström R.H., Lindqvist E., Mata de Urquiza A., Tomac A., Eriksson U., Perlmann T., Olson L. Role of retinoids in the CNS: differential expression of retinoid binding proteins and receptors and evidence for presence of retinoic acid. Eur. J. Neurosci. 1999, 11:407-416.
49. Zhang M., Ouagazzal A., Sun B., Creese I. Regulation of Motor Behavior by Dopamine Receptor Subtypes: An Antisense Knockout Approach 1996, Humana Press, New Jersey.